Results 131 to 140 of about 28,689 (318)

Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies

Journal of Dermatological Treatment
Purpose: Ruxolitinib (selective Janus kinase [JAK] 1 and JAK2 inhibitor) cream demonstrated efficacy and safety in patients with atopic dermatitis (AD) in the phase 3 TRuE-AD studies. In TRuE-AD1/TRuE-AD2 (NCT03745638/NCT03745651), adults and adolescents
Eric L. Simpson, Robert Bissonnette, Zelma C. Chiesa Fuxench, Howard Kallender, Daniel Sturm, Haobo Ren, Linda F. Stein Gold   +6 more
doaj   +1 more source

Heterogeneity of Cellular Senescence: Subtype‐Specific Mechanisms and the Emerging Role of Plasma Membrane Damage

Cancer Science, EarlyView.
Just as the term “cancer cell” encompasses a wide spectrum of cells, the term “senescent cell” should also be regarded as an umbrella term that includes cells with heterogeneous molecular profiles. In this review, we provide an updated overview of the molecular mechanisms underlying distinct senescent cell subtypes induced by various stimuli, including
Enaam Alghamdi, Keiko Kono
wiley   +1 more source

Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease

Case Reports in Transplantation, 2018
Ruxolitinib is an oral selective Janus-associated kinase 1 (JAK1) and JAK2 inhibitor that was initially approved by the FDA in 2014 for treatment of myelofibrosis.
Allison P. Watson, Claudio G. Brunstein, Shernan G. Holtan   +2 more
doaj   +1 more source

Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis [PDF]

, 2013
Srđan Verstovšek
openalex   +1 more source

New Topical and Systemic Treatments for Atopic Dermatitis

Clinical &Experimental Allergy, EarlyView.
This review summarises new topical and systemic treatments for atopic dermatitis, their relative effectiveness, and important safety data. ABSTRACT Atopic dermatitis is an inflammatory skin condition characterised by pruritus and a chronic relapsing–remitting course.
Sara Mirali, Aaron M. Drucker
wiley   +1 more source

Ruxolitinib for the treatment of myelofibrosis: its clinical potential

Therapeutics and Clinical Risk Management, 2012
Alen Ostojic1, Radovan Vrhovac1, Srdan Verstovsek21Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, Zagreb, Croatia; 2Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX ...
Ostojic A, Vrhovac R, Verstovsek S
doaj  

Cord blood T regulatory cells synergize with ruxolitinib to improve GVHD outcomes

Frontiers in Transplantation
BackgroundAdoptive therapy with umbilical cord blood (UCB) T-regulatory (Treg) cells can prevent graft vs. host disease (GVHD). We hypothesize that UCB Tregs can treat GVHD and synergize with ruxolitinib, Jak2 inhibitor, to improve outcomes.MethodsUCB ...
Ke Zeng, Hongbing Ma, Meixian Huang, Mi-Ae Lyu, Tara Sadeghi, Christopher R. Flowers, Simrit Parmar   +6 more
doaj   +1 more source

New drugs: Ruxolitinib [PDF]

, 2013

openalex   +1 more source

Well‐being in German patients with vitiligo in genital and visible areas – a pilot study

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background Only a few studies exist on the psychosocial impact of vitiligo in German patients, in particular those affected in genital and visible body areas. Methods This monocentric pilot study aimed to assess well‐being of adult patients with vitiligo and to compare sex, age, and clinical characteristics between patients with and without ...
Janne Ohlenbusch, Rachel Sommer, Kerstin Steinbrink, Markus Böhm   +3 more
wiley   +1 more source

The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia [PDF]

, 2018
Choi, Jaebok, DiPersio, John F, Schroeder, Mark A, Staser, Karl   +3 more
core   +2 more sources